Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05035953

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05035953
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05035953. Randomized; double masking; primary purpose treatment. Start 2021-09-13 (anticipated); primary completion 2023-09-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
Condition
Stroke, Ischemic
Intervention (Drug)
Edaravone Dexborneol
Intervention (Drug)
Placebo
Lead sponsor
Huashan Hospital (class: other)
Collaborator
Shanghai Stroke Association (class: not stated)

Record details

Record id
cardio:ct-nct05035953
Content hash
86a4d8aab556b8d5b4d2c8dcd407b4248abc724a409f2ba6827186c2a82823b9